Simeprevir API Manufacturers

compare suppliers & send inquiries for free



Selected filters:

Country of origin

Located in:

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

Send inquiry

Replies slower than most

Located in:

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • DMF

  • CoA

Send inquiry

Not active

How does it work?

Register for free

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

Start sourcing

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

Send inquiries

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

Get quotation

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

Arrange agreement

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Simeprevir API 923604-59-5?

Here you will find a list of producers, manufacturers and traders of Simeprevir. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Cas Number:
DrugBank number:
Unique Ingredient Identifier:

About Simeprevir

Why are professionals looking for Simeprevir? Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to Boceprevir and Telaprevir but is classified as a second generation protease inhibitor. This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs. Broad use of simeprevir occurred when it was used in combination with a newer drug, Sofosbuvir.

Inhibiting HCV NS3/4A protease in a potent and highly specific manner, simeprevir is a direct-acting antiviral agent against the hepatitis C virus. Since the viral protease NS3/4A complex is essential for cleaving the HCV encoded polyprotein into individual viral proteins facilitating replication the drug blocks the viral replication process. It is shown to display synergistic effects with interferon-α and HCV NS5B inhibitor, and additive effects with ribavirin in HCV replicon cells Unlike first generation serine protease inhibitors, simprevir has a sightly different resistance profile where limited therapeutic efficacy of the drug is observed with NS3 Q80K polymorphic variants and simeprevir-specific amino acid position of 168 also results in higher treatment failure rates The observed prevalence of the N3 Q80K polymorphism was 30% in subjects infected with HCV genotype 1a and 0.% in subjects infected with HCV genotype 1b According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), simeprevir can be used as first-line or second-line threapies for treatment-naïve patients as adjunct to sofosbuvir treatment for genotype 1 or PEG-Interferon/ribavirin combination therapy for genotype 1 or The combination therapy of simeprevir and other antiviral agents are initiated in HCV-positive patients with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality.

Check who is selling Simeprevir in the overview above.

Simeprevir is a type of HCV polymerase inhibitors

HCV polymerase inhibitors are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the treatment of Hepatitis C virus (HCV) infections. These inhibitors target the RNA-dependent RNA polymerase (NS5B) enzyme, which plays a crucial role in the replication of the HCV virus within human cells.

By specifically inhibiting NS5B, these pharmaceutical compounds effectively hinder viral replication, reducing viral load and helping to control the progression of HCV infection. HCV polymerase inhibitors are commonly used in combination with other antiviral agents, such as direct-acting antivirals (DAAs), to achieve optimal therapeutic outcomes.

One of the key advantages of HCV polymerase inhibitors is their high potency and specificity against the NS5B enzyme, which minimizes the risk of off-target effects and increases the likelihood of successful treatment. Moreover, these inhibitors have shown excellent efficacy against a broad range of HCV genotypes, making them suitable for patients with diverse viral strains.

Researchers and pharmaceutical companies continue to innovate and develop new HCV polymerase inhibitors with enhanced efficacy and improved safety profiles. Ongoing efforts in this field aim to expand treatment options, reduce treatment durations, and improve the overall cure rates for patients infected with HCV.

In conclusion, HCV polymerase inhibitors are essential components of modern antiviral therapy for Hepatitis C. Their targeted inhibition of the NS5B enzyme demonstrates significant clinical benefits, providing patients with more effective and personalized treatment options, ultimately improving their quality of life.

Simeprevir (HCV polymerase inhibitors), classified under Anti-infective Agents

Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.

Simeprevir manufacturers | traders | suppliers

We have 2 companies offering Simeprevir from 2 different countries.

Get in contact with the supplier of your choice:

  • Dalian Wista Pharma Co Ltd from China
  • Janssen Pharma from Belgium

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.